CLINICAL TRIALS PROFILE FOR TALAMPANEL
✉ Email this page to a colleague
Clinical Trials for Talampanel
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00034814 ↗ | Multicenter Trial for Adults With Partial Seizures | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients. |
NCT00034814 ↗ | Multicenter Trial for Adults With Partial Seizures | Completed | Teva Pharmaceutical Industries | Phase 2 | To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients. |
NCT00036296 ↗ | Effects of Talampanel on Patients With Advanced Parkinson's Disease | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1/Phase 2 | The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson's disease. It is not clear why people with Parkinson's disease develop involuntary movements (dyskinesias) but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements. Talampanel is a drug which blocks these receptors. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Talampanel
Condition Name
Clinical Trial Locations for Talampanel
Trials by Country
Clinical Trial Progress for Talampanel
Clinical Trial Phase
Clinical Trial Sponsors for Talampanel
Sponsor Name